Current challenges in HER2-positive breast cancer

  • Puglisi F
  • Fontanella C
  • Amoroso V
 et al. 
  • 2


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


The introduction of trastuzumab into routine clinical practice has had a dramatic effect on the outlook for patients with HER2-positive breast cancer. Nevertheless, answers to some long unresolved questions about the optimal use of trastuzumab (such as its role in small tumors or low-risk disease, cardiac safety in the elderly, and treatment duration) have emerged only relatively recently. Moreover, with the availability of new highly effective HER2-directed therapies, including pertuzumab and trastuzumab-emtansine (T-DM1), the treatment algorithm for HER2-positive breast cancer continues to evolve.This review provides a summary of the latest evidence providing insight into the management of early and advanced HER2-positive breast cancer and delineates future perspectives of study and treatment for these patients.

Author-supplied keywords

  • adjuvant
  • breast cancer
  • breast carcinogenesis
  • cancer chemotherapy
  • clinical effectiveness
  • disease activity
  • disease association
  • drug efficacy
  • drug mechanism
  • drug response
  • epidermal growth factor receptor 2
  • human
  • metastasis potential
  • molecular pathology
  • outcome assessment
  • patient selection
  • prediction
  • pregnancy
  • protein determination
  • protein function
  • protein targeting
  • review
  • trastuzumab
  • treatment duration

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • F Puglisi

  • C Fontanella

  • V Amoroso

  • G V Bianchi

  • G Bisagni

  • C Falci

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free